Market Research Logo

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Japan, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd Key Recent Developments

Jul 16,2018: Lupin's Goa facility gets approval from UK MHRA
Jul 10,2018: Lupin appoints Yashwant Mahadik as President - Global HR
Jul 05,2018: Trend Micro secures Lupin's vast IT environment
Jun 29,2018: Lupin announces tie-up with European Association of Urology (EAU)
May 31,2018: Lupin appoints Nicholas Hart as President – Specialty for US Business

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Lupin Ltd - Key Facts
Lupin Ltd - Key Employees
Lupin Ltd - Key Employee Biographies
Lupin Ltd - Major Products and Services
Lupin Ltd - History
Lupin Ltd - Company Statement
Lupin Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Lupin Ltd - Business Description
R&D Overview
Lupin Ltd - Corporate Strategy
Lupin Ltd - SWOT Analysis
SWOT Analysis - Overview
Lupin Ltd - Strengths
Lupin Ltd - Weaknesses
Lupin Ltd - Opportunities
Lupin Ltd - Threats
Lupin Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Lupin Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 16, 2018: Lupin's Goa facility gets approval from UK MHRA
Jul 10, 2018: Lupin appoints Yashwant Mahadik as President - Global HR
Jun 29, 2018: Lupin announces tie-up with European Association of Urology (EAU)
May 31, 2018: Lupin appoints Nicholas Hart as President – Specialty for US Business
May 15, 2018: Lupin announces fiscal year 2018 Results, Board recommends dividend of 250%
May 14, 2018: Lupin's Nagpur facility US FDA inspection concluded with no observations
May 10, 2018: Lupin launches Corcal Bone and Beauty supplement
Apr 09, 2018: Lupin’s Softovac in The Economic Times ‘Promising Brands of 2018’
Apr 09, 2018: Lupin’s Softovac In Economic Times ‘Promising Brands Of 2018
Apr 06, 2018: Lupin's Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Lupin Ltd, Key Facts
Lupin Ltd, Key Employees
Lupin Ltd, Key Employee Biographies
Lupin Ltd, Major Products and Services
Lupin Ltd, History
Lupin Ltd, Other Locations
Lupin Ltd, Subsidiaries
Lupin Ltd, Joint Venture
Lupin Ltd, Key Competitors
Lupin Ltd, Ratios based on current share price
Lupin Ltd, Annual Ratios
Lupin Ltd, Annual Ratios (Cont...1)
Lupin Ltd, Annual Ratios (Cont...2)
Lupin Ltd, Interim Ratios
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Lupin Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Lupin Ltd, Performance Chart (2014 - 2018)
Lupin Ltd, Ratio Charts
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report